Brian A. Willis

1.7k total citations
48 papers, 905 citations indexed

About

Brian A. Willis is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Brian A. Willis has authored 48 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Physiology, 15 papers in Molecular Biology and 11 papers in Pharmacology. Recurrent topics in Brian A. Willis's work include Alzheimer's disease research and treatments (28 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers) and Computational Drug Discovery Methods (10 papers). Brian A. Willis is often cited by papers focused on Alzheimer's disease research and treatments (28 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (12 papers) and Computational Drug Discovery Methods (10 papers). Brian A. Willis collaborates with scholars based in United States, United Kingdom and Singapore. Brian A. Willis's co-authors include Sergey Shcherbinin, John R. Sims, Ivelina Gueorguieva, Paula T. Trzepacz, Stephen L. Lowe, Paul Ardayfio, Peng Yu, Laiyi Chua, Cynthia Evans and Andrew J. Saykin and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics and Journal of Alzheimer s Disease.

In The Last Decade

Brian A. Willis

47 papers receiving 888 citations

Peers

Brian A. Willis

PHYSI

PMH

PHARM

CTM

Neda Minakaran United Kingdom

Ying Tian United States

Robert A. Swarm United States

Karen C. Holdridge United States

Keith M. Gregg United States

Virginia Pérez‐Grijalba Spain

Sharon Sawchak United States

Ahmadul Kadir Sweden

Alessandra Bizzarro Italy

Celedon Gonzales United States

Neda Minakaran United Kingdom

Brian A. Willis

326 ×0.6

PHYSI

378 ×1.2

PMH

282 ×0.9

PHARM

70 ×0.4

CTM

138 ×0.9

Citations per year, relative to Brian A. Willis Brian A. Willis (= 1×) peers Neda Minakaran

Countries citing papers authored by Brian A. Willis

Since Specialization

Citations

This map shows the geographic impact of Brian A. Willis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Willis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Willis more than expected).

Fields of papers citing papers by Brian A. Willis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Willis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Willis. The network helps show where Brian A. Willis may publish in the future.

Co-authorship network of co-authors of Brian A. Willis

This figure shows the co-authorship network connecting the top 25 collaborators of Brian A. Willis. A scholar is included among the top collaborators of Brian A. Willis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian A. Willis. Brian A. Willis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Majid, Oneeb, Youfang Cao, Brian A. Willis, et al.. (2024). Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2111–2123. 6 indexed citations

Charil, Arnaud, Youfang Cao, Brian A. Willis, et al.. (2024). Lecanemab Slows Tau PET Accumulation. Alzheimer s & Dementia. 20(S6). 3 indexed citations

Teunissen, Charlotte E., Brian A. Willis, Robert Bell, et al.. (2024). Long‐Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma. Alzheimer s & Dementia. 20(S6). 1 indexed citations

Gueorguieva, Ivelina, Brian A. Willis, Laiyi Chua, et al.. (2023). Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(2). e12404–e12404. 14 indexed citations

Gueorguieva, Ivelina, Brian A. Willis, Laiyi Chua, et al.. (2023). Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. Clinical Pharmacology & Therapeutics. 113(6). 1258–1267. 46 indexed citations

Willis, Brian A., Albert Lo, Jeffrey L. Dage, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial. Journal of Alzheimer s Disease Reports. 7(1). 1015–1024. 8 indexed citations

Willis, Brian A., Ziad Hussein, Seiichi Hayato, et al.. (2023). Exposure‐response modeling to describe the change in brain amyloid following lecanemab administration in patients with early Alzheimer’s disease. Alzheimer s & Dementia. 19(S21). 1 indexed citations

Gueorguieva, Ivelina, Laiyi Chua, Kay Hoong Chow, et al.. (2023). Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease. Alzheimer s & Dementia. 19(S7). 1 indexed citations

Gueorguieva, Ivelina, Laiyi Chua, Brian A. Willis, John R. Sims, & Alette M. Wessels. (2022). Disease progression model using the integrated Alzheimer's Disease Rating Scale. Alzheimer s & Dementia. 19(6). 2253–2264. 9 indexed citations

10.

Shcherbinin, Sergey, Cynthia Evans, Ming‐Chi Lu, et al.. (2022). Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes. JAMA Neurology. 79(10). 1015–1015. 117 indexed citations

11.

Lo, Albert, Cynthia Evans, Michele Mancini, et al.. (2021). Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia. Journal of Alzheimer s Disease Reports. 5(1). 321–336. 22 indexed citations

12.

Lowe, Stephen L., Cynthia Evans, Sergey Shcherbinin, et al.. (2021). Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. The Journal of Prevention of Alzheimer s Disease. 8(4). 414–424. 74 indexed citations

13.

Willis, Brian A., et al.. (2015). Bloodstream Infection Caused by Mucor velutinosus. Infectious Diseases in Clinical Practice. 24(1). e3–e4. 6 indexed citations

14.

Trzepacz, Paula T., Andrew J. Saykin, Peng Yu, et al.. (2013). Subscale Validation of the Neuropsychiatric Inventory Questionnaire: Comparison of Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center Cohorts. American Journal of Geriatric Psychiatry. 21(7). 607–622. 44 indexed citations

15.

Willis, Brian A., Stephen L. Lowe, Stuart Friedrich, et al.. (2012). The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole. Drug Metabolism and Disposition. 40(10). 1945–1952. 1 indexed citations

16.

Yu, Peng, Robert A. Dean, Stephen D. Hall, et al.. (2012). Enriching Amnestic Mild Cognitive Impairment Populations for Clinical Trials: Optimal Combination of Biomarkers to Predict Conversion to Dementia. Journal of Alzheimer s Disease. 32(2). 373–385. 27 indexed citations

17.

Zhang, Wei, et al.. (2012). QT effect of semagacestat at therapeutic and supratherapeutic doses. International Journal of Clinical Pharmacology and Therapeutics. 50(4). 290–299. 2 indexed citations

18.

Trzepacz, Paula T., Jeffrey L. Cummings, Tammy Forrester, et al.. (2012). Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics. 25(5). 707–719. 43 indexed citations

19.

Willis, Brian A., et al.. (2011). Semagacestat Pharmacokinetics Are Not Significantly Affected by Formulation, Food, or Time of Dosing in Healthy Participants. The Journal of Clinical Pharmacology. 52(6). 904–913. 9 indexed citations

20.

Nakano, Masako, Brian A. Willis, Stuart Friedrich, et al.. (2011). Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease. Clinical Neuropharmacology. 35(1). 25–29. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact